The Damon Runyon Board is extraordinarily committed to supporting the best young minds in cancer research. We are singularly focused on this mission.”


Alan M. Leventhal

Chairman and CEO Beacon Capital Partners, LLC Boston, Massachusetts

Vice Chair, Scientific Programs

William G. Kaelin, Jr., MD
Professor, Department of Medicine
Dana-Farber Cancer Institutue
Boston, Massachusetts

Vice Chair, Investments and Treasurer

Leon G. Cooperman
Chairman and CEO Omega Advisors, Inc.
New York, New York

Vice Chair, Audit Committee and Secretary

Sanford W. Morhouse, Esq.
Of Counsel
Schulte Roth and Zabel LLP
New York, New York

While I select my investments based on return on investment, I select my charities based on impact. Year after year, Damon Runyon selects the best new minds in cancer research and funds their bold ideas for preventing and curing cancer. Year after year, its scientists go on to make major breakthroughs. That’s real impact.”

Leon G. Cooperman

Vice Chair, Board Development

Michael L. Gordon
Chief Executive Officer and Chief Investment Officer
Angelo, Gordon & Company LP
New York, New York

Vice Chair

David M. Beirne
General Partner, 10X Capital
Coral Gables, Florida



Vice Chair 

Deborah J. Coleman
Legal Counsel
Convexity Capital Management LP
Boston, Massachusetts

Steven J. Burakoff, MD
Dean for Cancer Innovation
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York

Robyn Coles
TRATE Properties
Boston, Massachusetts

Gary E. Erlbaum
Greentree Properties
Ardmore, Pennsylvania

Thomas J. Fahey, Jr., MD
Senior Vice President Emeritus
Memorial Sloan-Kettering Cancer Center
New York, New York

Buck French
General Partner
10X Capital
San Francisco, California

Elaine V. Fuchs, PhD
Rebecca C. Lancefield Professor
Investigator, Howard Hughes Medical Institute
Head, Laboratory of Mammalian Cell Biology and Development
The Rockefeller University
New York, New York

Receiving a Damon Runyon Fellowship had a tremendous impact on my scientific career. I also have been fortunate to mentor new Damon Runyon scientists in my lab who have gone on to have exemplary independent careers. Damon Runyon builds generations of scientific leaders and mentors.”

Elaine Fuchs, PhD

(Damon Runyon Fellow ‘77-‘79)

Richard B. Gaynor, MD
President of Research and Development
Neon Therapeutics
Cambridge, Massachusetts


Todd R. Golub, MD
Chief Scientific Officer Director, Cancer Program
The Broad Institute of MIT and Harvard
Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute
Professor of Pediatrics at Harvard Medical School
Investigator, Howard Hughes Medical Institute
Cambridge, Massachusetts

Scott Greenstein
President, Chief Content Officer
New York, New York

Steve Hayden
Vice Chairman & Chief Creative Officer (Retired)
Ogilvy & Mather Worldwide
New York, New York

Jay W. Ireland
President and CEO
GE Africa
Nairobi, Kenya

Morana Jovan-Embiricos, PhD
Managing Partner
F2 Capital Ventures, LLP
London, UK

Steven A. Kandarian
Chairman, President and CEO
MetLife, Inc
New York, New York

Noah Knauf
Managing Director
Warburg Pincus
San Francisco, California

Gabrielle Layton, PhD
Palo Alto, California

David M. Livingston, MD
Deputy Director
Dana-Farber/Harvard Cancer Center
Emil Frei Professor of Genetics and Medicine
Harvard Medical School                                         Boston, Massachusetts

David G. Marshall
Chairman and CEO
Amerimar Realty Company
Philadelphia, Pennsylvania

John H. Myers
Academy Securities
Fairfield, Connecticut

Richard J. O’Reilly, MD
Chief, Pediatric Bone Marrow Transplant Service
Claire L. Tow Chair in Pediatric Oncology Research
Memorial Sloan Kettering Cancer Center
New York, New York

Andrew S. Rachleff
President & CEO
Wealthfront, Inc.
Palo Alto, California

William Raveis, Jr.
Founder, Chairman and CEO
William Raveis Real Estate, Mortgage & Insurance
Southport, Connecticut

In Silicon Valley, we have witnessed brilliant young minds with bold ideas change the world. Damon Runyon makes this happen for cancer research. It identifies top emerging talent and encourages their high risk/high reward ideas. The payoff has been generations of game-changers.”

Andy and Debbie Rachleff

Michael V. Seiden, MD, PhD
Senior Vice President and Chief Medical Officer
McKesson Specialty Health
The US Oncology Network
The Woodlands, Texas

Karen D. Seitz
Founder and Managing Director
Fusion Partners
New York, New York

Nancy Simonian, MD
Chief Executive Officer
Syros Pharmaceuticals
Watertown, Massachusetts

Cynthia Sulzberger
Palm Beach, Florida

Peter Van Camp
Executive Chairman
Equinix, Inc.
Redwood City, California

James A. Wells, PhD
Chairman, Dept. of Pharmaceutical Chemistry
University of California at San Francisco
San Francisco, California